K
Kymera Therapeutics Inc (KYMR)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
$121.52
-4.33 (-3.44%)
Market Cap: $10.74B
Last updated: Nov 17, 2026 at 4:35 PM ET
Kymera Therapeutics Inc (KYMR) Valuation Multiples
Kymera Therapeutics (KYMR) trades at 119.0x sales and 7.5x book value. Its P/S of 119.0x is above its 5-year median of 34.9x.
Current Multiples
| Multiple | Value |
|---|---|
| P/E (trailing) | N/A |
| Forward P/E | N/A |
| Price to sales | 119.0x |
| Price to book | 7.5x |
| PEG | N/A |
| FCF yield | -2.4% |
Historical Medians
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/S | 119.0x | 34.9x | N/A |
| P/B | 7.5x | 3.8x | N/A |
Valuation History
Over the 6 year ends shown, its P/S ranged from 18.9x in 2023 to 160.7x in 2025. 2025 was the highest of those years.
| Year end | Price | P/S | P/B |
|---|---|---|---|
| 2025 | $77.81 | 160.7x | 4.2x |
| 2024 | $40.23 | 63.1x | 3.9x |
| 2023 | $25.46 | 18.9x | 3.8x |
| 2022 | $24.96 | 28.9x | 2.9x |
| 2021 | $63.49 | 41.6x | 7.1x |
| 2020 | $62.00 | 54.2x | 9.7x |
Frequently Asked Questions About KYMR
What is KYMR's price to sales ratio?
Kymera Therapeutics has a price to sales ratio of 119.0x.
KYMR pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors